BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gavriilaki E, Sakellari I, Batsis I, Mallouri D, Bousiou Z, Vardi A, Yannaki E, Constantinou V, Tsompanakou A, Vadikoliou C, Kaloyannidis P, Bamihas G, Anagnostopoulos A. Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation. Clin Transplant 2018;32:e13371. [DOI: 10.1111/ctr.13371] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Chan WYK, Ma ALT, Chan EYH, Kan ANC, Ng WF, Lee PPW, Cheuk DKL, Chiang AKS, Leung W, Chan GCF. Epidemiology and outcomes of pediatric transplant-associated thrombotic microangiopathy in Hong Kong. Pediatr Transplant 2022;:e14366. [PMID: 35860972 DOI: 10.1111/petr.14366] [Reference Citation Analysis]
2 Ardissino G, Capone V, Tedeschi S, Porcaro L, Cugno M. Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy. Pharmaceuticals (Basel) 2022;15:845. [PMID: 35890144 DOI: 10.3390/ph15070845] [Reference Citation Analysis]
3 Higham CS, Shimano KA, Melton A, Kharbanda S, Chu J, Dara J, Winestone LE, Hermiston ML, Huang JN, Dvorak CC. A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high-risk pediatric patients. Pediatr Blood Cancer 2022;69:e29641. [PMID: 35253361 DOI: 10.1002/pbc.29641] [Reference Citation Analysis]
4 Jodele S, Dandoy CE, Sabulski A, Koo J, Lane A, Myers KC, Wallace G, Chima RS, Teusink-cross A, Hirsch R, Ryan TD, Benoit S, Davies SM. TA-TMA risk stratification: is there a window of opportunity to improve outcomes? Transplantation and Cellular Therapy 2022. [DOI: 10.1016/j.jtct.2022.04.019] [Reference Citation Analysis]
5 Zhang Z, Wang H, Qi J, Tang Y, Cai C, Zhou M, Pan T, Wu D, Han Y. Acute graft-versus-host disease increase risk and accuracy in prediction model of transplantation-associated thrombotic microangiopathy in patients with myelodysplastic syndrome. Ann Hematol 2022. [PMID: 35357522 DOI: 10.1007/s00277-022-04820-z] [Reference Citation Analysis]
6 Kaya AH, Tekgunduz E. Management of thrombotic microangiopathy after hematopoietic cell transplantation: A position statement of ThREG (Turkish Hematology Research and Education Group). Transfus Apher Sci 2021;:103313. [PMID: 34785151 DOI: 10.1016/j.transci.2021.103313] [Reference Citation Analysis]
7 Gavriilaki E, Sakellari I, Chatzikonstantinou T, Bousiou Z, Mallouri D, Masmanidou M, Vardi A, Koravou EE, Kika F, Touloumenidou T, Papalexandri A, Yannaki E, Batsis I, Anagnostopoulos A. Predictors of Transplant-Associated Thrombotic Microangiopathy in Patients With Overlap or Chronic Graft-vs-Host-Disease. Transplant Proc 2021;53:2261-6. [PMID: 34417030 DOI: 10.1016/j.transproceed.2021.07.043] [Reference Citation Analysis]
8 Eftychidis I, Sakellari I, Anagnostopoulos A, Gavriilaki E. Endothelial dysfunction and vascular complications after allogeneic hematopoietic cell transplantation: an expert analysis. Expert Rev Hematol 2021. [PMID: 34388057 DOI: 10.1080/17474086.2021.1968823] [Reference Citation Analysis]
9 Jodele S, Sabulski A. Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients. Expert Rev Hematol 2021;14:751-63. [PMID: 34301169 DOI: 10.1080/17474086.2021.1960816] [Reference Citation Analysis]
10 Okamura H, Nakamae H, Shindo T, Ohtani K, Hidaka Y, Ohtsuka Y, Makuuchi Y, Kuno M, Takakuwa T, Harada N, Nishimoto M, Nakashima Y, Koh H, Hirose A, Nakamae M, Wakamiya N, Hino M, Inoue N. Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy. Front Immunol 2021;12:695037. [PMID: 34326846 DOI: 10.3389/fimmu.2021.695037] [Reference Citation Analysis]
11 Li A, Gupta R, Amos CI, Davis C, Pao E, Lee SJ, Hingorani SR. Thrombotic microangiopathy increases the risk of chronic kidney disease but not overall mortality in long-term transplant survivors. Transplant Cell Ther 2021:S2666-6367(21)01030-7. [PMID: 34217847 DOI: 10.1016/j.jtct.2021.06.027] [Reference Citation Analysis]
12 Higham CS, Collins G, Shimano KA, Melton A, Kharbanda S, Winestone LE, Huang JN, Dara J, Long-Boyle JR, Dvorak CC. Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis. Blood Adv 2021;5:2106-14. [PMID: 33877298 DOI: 10.1182/bloodadvances.2020003988] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Matsui H, Arai Y, Imoto H, Mitsuyoshi T, Tamura N, Kondo T, Kanda J, Ishikawa T, Imada K, Ueda Y, Toda Y, Anzai N, Yago K, Nohgawa M, Yonezawa A, Tsunemine H, Itoh M, Yamamoto K, Tsuji M, Moriguchi T, Takaori-Kondo A; Kyoto Stem Cell Transplantation Group (KSCTG). Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT. Blood Adv 2020;4:3169-79. [PMID: 32658984 DOI: 10.1182/bloodadvances.2020002007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
14 Young JA, Pallas CR, Knovich MA. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transplant 2021;56:1805-17. [PMID: 33875812 DOI: 10.1038/s41409-021-01283-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Gavriilaki E, Sakellari I, Anyfanti P, Batsis I, Vardi A, Bousiou Z, Lazaridis A, Nikolaidou B, Zarifis I, Masmanidou M, Yiannaki E, Markala D, Anagnostopoulos A, Douma S, Gkaliagkousi E. Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation. Int J Mol Sci 2020;21:E9768. [PMID: 33371421 DOI: 10.3390/ijms21249768] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Gavriilaki E, Sakellari I, Chatzikonstantinou T, Mallouri D, Batsis I, Vardi A, Bousiou Z, Koravou EE, Masmanidou M, Touloumenidou T, Papalexandri A, Athanasiadou A, Yannaki E, Anagnostopoulos A. Endothelial and Complement Activation As Predictors of Survival in Adult Allogeneic Hematopoietic Cell Transplantation. Hemasphere 2021;5:e487. [PMID: 33324949 DOI: 10.1097/HS9.0000000000000487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
17 Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, Wallace G, Nelson A, Bleesing J, Chima RS, Hirsch R, Ryan TD, Benoit S, Mizuno K, Warren M, Davies SM. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood 2020;135:1049-57. [PMID: 31932840 DOI: 10.1182/blood.2019004218] [Cited by in Crossref: 14] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
18 Imus PH, Tsai HL, DeZern AE, Jerde K, Swinnen LJ, Bolaños-Meade J, Luznik L, Fuchs EJ, Wagner-Johnston N, Huff CA, Gladstone DE, Ambinder RF, Gocke CB, Ali SA, Borrello IM, Varadhan R, Brodsky R, Jones RJ. Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant 2020;26:2306-10. [PMID: 32961372 DOI: 10.1016/j.bbmt.2020.09.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sagou K, Fukushima N, Ukai S, Goto M, Ozeki K, Kohno A. Clinical usefulness of diagnostic criteria for transplant-associated thrombotic microangiopathy. Int J Hematol 2020;112:697-706. [DOI: 10.1007/s12185-020-02963-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Heybeli C, Sridharan M, Alkhateeb HB, Villasboas Bisneto JC, Buadi FK, Chen D, Dingli D, Dispenzieri A, Gertz MA, Go RS, Hashmi SK, Hayman SR, Hogan WJ, Inwards DJ, Kenderian SS, Kumar SK, Litzow MR, Porrata LF, Lacy MQ, Micallef IN, Patnaik MM, Shah MV, Leung N. Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. Am J Hematol 2020. [PMID: 32618000 DOI: 10.1002/ajh.25922] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
21 Hildebrandt GC, Chao N. Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation. Br J Haematol 2020;190:508-19. [PMID: 32319084 DOI: 10.1111/bjh.16621] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
22 Gavriilaki E, Sakellari I, Karafoulidou I, Pasteli N, Batsis I, Mallouri D, Lazaridou A, Iskas M, Vardi A, Papalexandri A, Tsompanakou A, Papaemmanouil S, Ilias A, Anagnostopoulos A. Intestinal thrombotic microangiopathy: a distinct entity in the spectrum of graft-versus-host disease. Int J Hematol 2019;110:529-32. [PMID: 31586304 DOI: 10.1007/s12185-019-02750-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
23 Yamada R, Nemoto T, Ohashi K, Tonooka A, Horiguchi SI, Motoi T, Hishima T. Distribution of Transplantation-Associated Thrombotic Microangiopathy (TA-TMA) and Comparison between Renal TA-TMA and Intestinal TA-TMA: Autopsy Study. Biol Blood Marrow Transplant 2020;26:178-88. [PMID: 31491486 DOI: 10.1016/j.bbmt.2019.08.025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
24 Sakellari I, Gavriilaki E, Papagiannopoulos S, Gavriilaki M, Batsis I, Mallouri D, Vardi A, Constantinou V, Masmanidou M, Yannaki E, Smias C, Geroukis T, Kazis D, Kimiskidis V, Anagnostopoulos A. Neurological adverse events post allogeneic hematopoietic cell transplantation: major determinants of morbidity and mortality. J Neurol 2019;266:1960-72. [PMID: 31087160 DOI: 10.1007/s00415-019-09372-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
25 Gavriilaki E, Gkaliagkousi E, Grigoriadis S, Anyfanti P, Douma S, Anagnostopoulos A. Hypertension in hematologic malignancies and hematopoietic cell transplantation: An emerging issue with the introduction of novel treatments. Blood Reviews 2019;35:51-8. [DOI: 10.1016/j.blre.2019.03.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
26 Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Front Immunol 2019;10:337. [PMID: 30891033 DOI: 10.3389/fimmu.2019.00337] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]